Phase I clinical trial (NCT02789254) with FLYSYN, an Fc-optimized antibody directed against FLT3/CD135, showed interesting results in eradicating MRD positivity in 35% of 31 patients with AML FLT3 mut [55]. Here, FLT3 is linked to acute myeloid leukemia.